Context Serotonin reuptake-inhibiting (SRI) antidepressants are the only FDAapproved pharmacotherapies for the treatment of posttraumatic stress disorder (PTSD).
P
OSTTRAUMATIC STRESS DISOR der (PTSD) is among the most common and disabling psychiatric disorders among military personnel serving in combat theaters. [1] [2] [3] Antidepressants are the pre dominant pharmacotherapy for PTSD. Two serotonin reuptake inhibitors (SRIs), sertraline and paroxetine, have Food and Drug Administration ap proval for the treatment of PTSD based on multicenter trials. [4] [5] [6] [7] Within the De partment of Veterans Affairs (VA), 89% of veterans diagnosed with PTSD and treated with pharmacotherapy are pre scribed SRIs. 8 However, SRIs appear to be less effective in men than in women 4 and less effective in chronic PTSD than in acute PTSD. 9, 10 Thus, it may not be surprising that an SRI study in veter ans produced negative results. ing this practice. 12, 13 In 2007, PTSD was the most common off-label diagnosis within the VA associated with an antipsychotic prescription. 14 In 2009, 86 852 veterans diagnosed with PTSD (19.9%) received an antipsychotic pre scription and 81 279 of these prescrip tions (93.6%) were for SGAs.
14 There are substantial safety concerns associ ated with SGAs, particularly risks for weight gain and extrapyramidal mo tor symptoms. 15 The current study evaluated whether risperidone, an SGA, when added to an ongoing pharmacotherapy regimen would be more effective than placebo for reducing chronic military-related PTSD symptoms among veterans whose symptoms did not respond to at least 2 adequate SRI treatments. To our knowledge, this study is the first large trial of a pharmacotherapy aimed at SRIresistant PTSD symptoms.
METHODS
Patients were eligible if they were at least 18 years old, participated in a military combat theater, met diagnos tic criteria for military service-related chronic PTSD on the basis of a struc tured interview for making psychiatric diagnoses according to the Diagnostic and Statistical Manual of Mental Disor ders (Fourth Edition) (DSM-IV), 16 had a Clinician-Administered PTSD Scale (CAPS) score greater than 50, 17 had a clinical history of intolerance of or nonresponse to 2 or more antidepres sants, and had an inadequate response to 2 adequate SRI treatments (mini mum of 4 weeks of pharmacotherapy each). Other eligibility criteria included having a fixed address within 50 miles of the research site or con firmed transportation for all visits, using an acceptable method of birth control (female patients), and giving written informed consent.
494 JAMA, August 3, 2011-Vol 306, No. 5 Patients were excluded if they met lifetime diagnostic criteria for bipolar disorder or schizophrenia; required an tipsychotic medication for the treat ment of psychosis; met diagnostic cri teria for dependence on a substance other than nicotine in the 30 days prior to screening; had clinical or labora tory evidence (levels of aspartate ami notransferase, alanine aminotransfer ase, bilirubin, blood urea nitrogen, or creatinine) of hepatic or renal compro mise; had a medical disorder that might increase the risks of risperidone treat ment (insulin-dependent diabetes) or complicate interpretation of study re sults (epilepsy, dementia); had a his tory of intolerance of antipsychotics; at tempted suicide or assaulted someone in the prior year; or had an impending legal incarceration. Although ongoing pharmacotherapy was allowed, pa tients receiving SGAs, serotonergic (5HT 2 ) receptor antagonists (cypro heptadine, methysergide, trazodone), a 1 receptor antagonists (prazosin), and a 2 receptor agonists/antagonists (clonidine, guanfacine, mirtazapine) were excluded initially.
Race and ethnicity of the partici pants were determined by self-reports with concurrence by the rater.
Interventions
The human subjects subcommittees of the VA Cooperative Studies Program and each participating VA Medical Cen ter approved this study. All patients gave written informed consent prior to study entry. An independent data safety monitoring board monitored patient safety throughout the study.
Patients were randomized to re ceive double-blinded 6-month treat ment with risperidone or matched pla cebo. Study medication (risperidone 1 mg or matching placebo) was initi ated at a dose of 1 tablet orally at bed time and increased by 1 tablet per week to a dose of 3 tablets at bedtime. After participants received study medica tion for 4 weeks, investigators who were blinded to study medication status and were treating patients had the option of further increasing the dose by 1 tab let (1 mg), providing medications were well tolerated and a dose increase was indicated clinically.
Prior to study entry, patients and their primary mental health care clini cians developed a treatment plan that would not violate study protocol and would be engaged if study medica tions were ineffective. These alterna tive treatments enabled some patients to remain as participants for the full 6 months of randomized treatment (eTable 1, available at http://www.jama .com). There were no significant dif ferences across groups in the fre quency with which these adjunctive medications from particular classes were initiated during the clinical trial.
Patients participated in a feedback program that was designed to en hance adherence to prescribed medi cations. 18, 19 Medication was provided in bottles with microelectronic monitor caps (MEMS; AARDEX Group, Union City, California) that recorded the date and time of each opening and showed the number of hours elapsed since the previous opening. The Medication Us age Skills for Effectiveness feedback sys tem, 18 in which data on the previous month's dosing were shown to pa tients at each visit, encouraged pa tients to take medication daily by train ing them to develop and use reminders that supported medication adherence.
Randomization and Treatment
Patients were recruited initially from 20 VA Medical Centers over a 2-year pe riod. To address low recruitment rates and other issues, 8 sites were discon tinued and 6 sites were added during the course of the study. A total of 26 sites were approved by the human sub jects subcommittee to enroll patients into the study. In addition, the recruit ment period was extended by 6 months, and patients who had initially been con sidered ineligible to participate in the study because they were receiving cer tain drugs (trazodone 드100 mg, ne fazodone 드100 mg, quetiapine 드25 mg, and mirtazapine 드30 mg) were al lowed if the drugs were prescribed for at least 3 months prior to screening and prescribed at the current dose for at least 1 month. A total of 83 patients (42 in the risperidone group, 41 in the pla cebo group) who were ultimately en rolled in this study had received at least 1 of these medications. Secondary analyses testing the effect of broaden ing the study entry criteria did not find any effects on the findings for the prin cipal outcome measures.
Randomized assignment of patients to treatment groups was conducted by the Cooperative Studies Program Co ordinating Center (Perry Point, Mary land). Calls requesting randomization went to a central location on the day the patient was deemed eligible and ready to start medication. Separate ran domization schedules were generated for each participating center, assign ing equal numbers of patients to each of the groups. Block sizes of 2 and 4 were used to balance assignments across groups and to prevent decoding of the system. Assignments were stratified within centers. Patients were evalu ated to ensure they met all eligibility cri teria before a randomization code was provided. Treatment was initiated within a day of randomization.
Outcome Measures
The primary outcome measure for this study was the total score on the 34 item CAPS. 20 This scale was adminis tered by trained raters who were blind to the randomization status of pa tients at baseline and weeks 6, 12, and 24. All raters underwent initial train ing and credentialing to administer and score the primary and secondary out come measures. They also completed annual training and reliability checks during the study to ensure that they met at least 80% reliability of their mea surement; all raters eventually met this reliability standard. Interrater reliabil ity was assessed at 2 annual subse quent time points. All raters showed 100% diagnostic accuracy at both ses sions, and median scores were within 0.5 points and 3 points at the 2 annual follow-ups, respectively.
The CAPS provided an overall mea sure of PTSD symptom severity. Second ary outcomes were assessed each time the CAPS was administered: the observerrated and patient-rated Clinical Global Impression scale (CGI), the Montgom ery-Asberg Depression Rating Scale (MADRS), 21 the Hamilton Anxiety Scale (HAMA), 22 a scale used to rate psychosis (Positive and Negative Syndrome Scale [PANSS]), 23 the Veterans RAND 36-Item Health Survey (SF-36V), 24 the 26-item Boston Life Satisfaction Inven tory (BLSI), 25 and a service utilization measure. At each visit, smoking was as sessed using the first 3 items of the Fag erströ m Scale, 26 and alcohol consump tion was evaluated using the timeline follow-back method for the 90 days prior to study entry and the interval between each visit. 27 Motor adverse events asso ciated with risperidone were assessed using the Barnes Akathisia Scale, 28 the Extrapyramidal Symptom Rating Scale, 29 and the Abnormal Involuntary Move ment Scale. 30 On all reported outcome measures except the SF-36V, higher scores reflect higher symptom levels. On the SF-36V, higher scores reflect higher quality of life. Valid baseline data were collected for 267 patients; the primary outcome analysis included 247 patients for whom a valid week-24 CAPS assessment was obtained.
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Data Analyses
Data were collected and analyzed by the VA Cooperative Studies Program. Base line characteristics were compared with x 2 and t tests as appropriate.
The primary outcome measure in this study was the intent-to-treat analysis of the improvement in PTSD symptoms from baseline to week-24 follow-up as measured by the CAPS. A 2-tailed t test was performed on these data using an a = .05. This study was powered ini tially to detect a 9-point difference between the treatment groups in the CAPS change score; assuming a 20% dropout rate and a power of 0.9, a target sample size of 205 patients per group was required. In the absence of a validated threshold for minimal important differ ence on the CAPS, the threshold of 9 points was derived from data suggest ing the following: (1) a 9-point decrease would be predicted to produce clearly evi dent changes in core PTSD symp toms 31, 32 ; (2) 9 points was estimated to be approximately 0.5 SD in severely symptomatic veterans with PTSD, 33 and across medical conditions score reduc tions of 0.5 SD are generally found to be a minimal important difference 34 ; and (3) 9-to 10-point decreases would be expected to be associated with improve ments in measures of quality of life. 35 The recruitment rate was lower than projected, with a total of 296 random ized patients rather than the targeted 410. However, both the dropout rate and the variance in the data were lower than pro jected, offsetting the effects of the ac tual sample size on the statistical power of the study. Two hundred forty-seven patients (123 per group, for purposes of power calculation) completed the study. Based on the original parameters for study sample size, an a=.05, and the es timated pooled 18.4 SD, this sample size provided 96.9% power to detect a 9-point difference between the groups in the pri mary outcome measure-ie, the differ ence between baseline and week-24 CAPS scores. In secondary and exploratory analy ses, the CAPS, its subscales, and all other continuous outcome measures were analyzed using mixed models, 36 covarying for baseline values and using all available outcome data. The mod els initially had fixed effects for treat ment group and time. The interac tions between treatment and time effects were dropped because they were not significant in reported analyses. Site and patient were treated as random ef fects. Generalized least squares means of treatment effect were computed within the SAS mixed linear models procedures (MIXED and GLIMMIX) used to analyze outcome data (SAS In stitute, Cary, North Carolina). These least squares means are estimators of the treatment means that would be ex pected for a balanced design.
In post hoc analyses, the severity of the 3 component clusters of PTSD symptoms associated with DSM IV-TR diagnostic criteria 37 -reexperi encing, avoidance/numbing, and hy perarousal 20 -were analyzed separately with Bonferroni adjustments for mul tiple comparisons. Also, treatment ef fects on PTSD severity categories based on the CAPS 32 were analyzed using a 2-tailed x 2 test. This analysis yielded an estimate of medication effects on re mission rates in this study as defined by a CAPS score of less than 20. 38 A comparison of the treatment groups on retention in the study was based on survival analysis of time (days) receiv ing study medication as measured from the day of randomization to the day of last dose. Survival curves for study re tention were estimated for each treat ment group with Kaplan-Meier meth odology (SAS procedure LIFETEST), and treatment group comparisons were based on the log-rank test. 
Retention
Rates of retention while receiving ran domized treatment were high and did not differ by group (log-rank test x 1 2 = 0.71, P = .40) (eFigure 1). How ever, patients treated with placebo con tinued receiving assigned medication on average approximately 1 week longer than patients treated with risperidone (risperidone: median, 166.5 days; mean, 133.1 days; 95% confidence interval [CI], 123.6-142.6 days; placebo: me dian, 167.0 days; mean, 148.9 days; 95% CI, 141.5-156.4 days; t = 2.59; Satter thwaite df=238.87; P =.01).
Treatment Effects
There were no significant effects of ris peridone treatment on the primary out come measure, the change in CAPS total score from baseline to 24 weeks (ris peridone: −16.3; 95% CI, −19.7 to −12.9; placebo: −12.5; 95% CI, −15.7 to −9.4; mean difference, 3.74; 95% CI, −0.86 to 8.35; t = 1.6; P = .11). In the mixed model of CAPS total scores, the effect of medication was also not sig nificant (F 1,253 =2.30; P=.13), but symp tom scores decreased over time in both groups (F 2,488 =9.94; P<.001) (FIGURE 2 and TABLE 4). Baseline CAPS score (F 1, 253 =257.67; P <.001), but not the war in which the veteran served, was associated with higher CAPS score throughout the study. Neither effect in teracted significantly with medication group and controlling for their effects did not alter the findings.
To further explore whether risperi done produced clinically significant changes on the CAPS, the distribution of patients in each treatment group was determined following a published cat egorization of PTSD status 32 30 ). This analysis also provided information about the rate of remission of patients in each group because a CAPS score of less than 20 is a validated remission threshold. 38 The rate of remission in patients treated with placebo (4%) did not differ significantly from patients treated with risperidone (5%) (eFigure 2).
In post hoc Bonferroni-adjusted analyses (P = .02) of CAPS subscales using mixed regression models, ris peridone was associated with signifi cantly reduced symptoms as mea sured by the CAPS reexperiencing subscale (F 1 , 2 5 3 = 8.16, P = .005, d = 0.298) and the CAPS hyperarousal subscale (treatment: F 1,253 = 8.09, P = .005, d = 0.318; treatment × week interaction: F 2,486 = 4.11, P = .02), but not the CAPS avoidance/numbing subscale (F 1 , 2 5 3 = 1.23, P = .27). Assuming a 0.5-SD threshold for the minimal clinically important differ ence, the statistically significant find ings for the CAPS subscales do not meet this threshold. This suggests that although statistically significant, the changes on the CAPS scales would not be recognized by many clinicians as meaningful.
Consistent with the CAPS findings, no medication effects on the observerrated version ( Adverse Events (continued) Adverse events that occurred in at least 5% of the overall sample are reported in eTable 5. Overall, the rate of ad verse events during treatment was low but appeared related to dosing of ris peridone. The study protocol targeted a risperidone dose of 3 mg/day and al lowed clinicians to increase the dose to 4 mg if indicated. With these instruc tions, the modal medication dose was 4 mg for both groups. By the end of the study, patients randomized to receive placebo were receiving 3.35 mg of pla cebo on average, suggesting that clini cians were satisfied with the clinical progress of many patients treated with placebo. However, patients random ized to risperidone were receiving on average a dose of 2.74 mg. This sug gests, consistent with our clinical im pressions, that adverse effects limited some patients from achieving the tar get dose of 3 mg. This study was un able to determine whether adverse ef fects limited the efficacy of risperidone, but perhaps these data suggest that fu ture studies should explore doses lower than 3 mg of risperidone.
However, there were significantly more cases in the group treated with risperidone of self-reported weight gain (risperidone: n = 20, 15.3%; placebo: n=3, 2.3%), fatigue (risperidone: n=18, 13.7%; placebo: n=0), somnolence (risperidone: n=13, 9.9%; placebo: n = 2, 1.5%), and hypersalivation (risperidone: n=13, 9.9%; placebo: n=1, 0.8%) (eTable 5). Risperidone did not in crease measured weight significantly (F 1,235 =2.86, P=.09) . Also, there were no significant effects of risperidone on the 3 measures of extrapyramidal symptoms in this study, the Barnes Akathisia Scale, the Extrapyramidal Symptom Rating Scale, and the Abnormal Involuntary Movement Scale. 
COMMENT
In this study, there was no statistically significant difference between risperi done and placebo in reducing CAPS total scores when prescribed for 6 months as an adjunct to SRIs and other ongoing medication and psychosocial treatments in a group of highly symp tomatic veterans with medicationresistant symptoms associated with chronic military-related PTSD. Com pared with placebo, risperidone pro duced only a 3.74-point greater reduc tion from baseline in the CAPS total score. Thus, it is unlikely that clini cians could detect the magnitude of the risperidone effect over placebo that was observed in this study. In addition, ris peridone was not statistically superior to placebo on any of the secondary out comes, including the observer-and selfrated versions of the Clinical Global Im pressions scale; quality of life (SF-36V or BLSI); and measures of depression (MADRS), anxiety (HAMA), or para noia/psychosis (PANSS positive symp tom subscale).
Adverse events associated with ris peridone were not serious. Post hoc analyses of the CAPS, adjusted for mul tiple comparisons, suggested that ris peridone was associated with a signifi cant reduction in reexperiencing and hyperarousal symptoms associated with PTSD with a small effect size. Al though the findings were significant statistically, these changes were smaller than the 0.5-SD threshold used to de fine the minimal important difference in estimating the sample size for this study. 34 Thus, it is questionable whether the observed changes on these sub scales would be detected clinically.
However, this study could not rule out the possibility that risperidone treat ment addressed a real clinical need for some patients. The ability of risperi done to reduce reexperiencing and hy perarousal symptoms, such as dis rupted sleep and autonomic arousal, is consistent with its ability to block 5-HT 2A and a 1 adrenergic receptors. 39 This hypothesis is supported by the widespread prescription of trazodone, a 5-HT 2 receptor antagonist, for sleep impairment associated with PTSD. 40 It is also consistent with the increasing evidence of the efficacy of prazosin, an a 1 adrenergic receptor antagonist, for treating reexperiencing and hyperarousal symptoms of PTSD. [41] [42] [43] The lack of efficacy of adjunctive ris peridone on CAPS total scores and global outcome measures in this study contrasts with positive findings from some smaller randomized trials [4] [5] [6] [7] [8] [9] [10] [11] 44 but is consistent with a study of SRIresistant civilian PTSD. 45 However, the lack of risperidone efficacy on avoid ance/emotional numbing symptoms On all reported outcome measures except SF-36V, higher scores reflect higher symptom levels; higher scores on SF-36V reflect higher quality of life. This study has several limitations. This study did not achieve the prespeci fied sample size of 410 patients projected for this study. Further, source documentation for 29 patients was inadvertently lost, invalidating their data. These 29 patients (9.8% of all randomized study participants) were enrolled at 2 of the original study sites. After the loss of data was discovered, the 29 pa tients were excluded from further analy ses and enrollment was discontinued at both sites. At 1 of these sites, enroll ment was later restarted with a new site investigator. Because our analyses con trolled for clustering by study site, it is unlikely that the loss of patient data from these 2 sites would have biased the results, which were based only on pa tient data from the 23 other study sites. In addition, the study participants in these 2 sites were balanced with re spect to treatment group (14 in the risperidone group and 15 in the placebo group), so pre-existing biases were likely to have been distributed equally across treatment groups. Even after ex cluding these 29 patients, our study had adequate statistical power to detect a clinically meaningful benefit of risperi done, if a true benefit had existed.
Patient retention in the study was greater than expected and variance within the data was less than expected. Based on the 247 patients who completed the study and the prespeci fied factors in the power analysis, this study had 96.6% power to detect a 9-point difference in the ability of ris peridone and placebo to reduce CAPS total score during treatment, a change that might be considered a minimal im portant difference. However, even if the full projected sample had been re cruited, this study most likely would not have yielded statistical signifi cance for the small differential change in CAPS total scores produced by ris peridone and placebo (3.74 points).
A second limitation is that study en try criteria were relaxed because of re cruitment problems; patients were ac cepted who had long-standing prescriptions of low doses of com monly prescribed sleep medications, particularly trazodone and quetiap ine. Although adjusting for this effect did not alter the findings with respect to the CAPS, including these patients may have reduced the expected effects of risperidone in the current study. Third, it is not clear that the findings generalize to other SGAs, such as olanzapine or quetiapine, that may have somewhat different clinical profiles in PTSD. 10 Fourth, it remains to be deter mined whether the findings general ize to women because the study popu lation was nearly entirely men. Analyses conducted to adjust for the effect of dif fering combat theaters did not alter the findings related to the primary out come measure, but this study was not designed explicitly to explore the in teraction of combat theater and treat ment response. Fifth, this study evalu ated the efficacy of adjunctive risperidone treatment, and the find ings may not generalize to risperidone prescribed by itself for the treatment of PTSD.
In summary, risperidone, the sec ond most widely prescribed SGA within VA for PTSD and the best datasupported adjunctive pharmaco therapy for PTSD, 12 did not reduce over all PTSD severity (CAPS total score), produce global improvement (CGI score), or increase quality of life (SF 36V) in patients with chronic SRIresistant military-related PTSD symp toms. Overall, the data do not provide strong support for the current wide spread prescription of risperidone to pa tients with chronic SRI-resistant mili tary-related PTSD symptoms, and these findings should stimulate careful re view of the benefits of these medica tions in patients with chronic PTSD.
